98%
921
2 minutes
20
Background: Immunoglobulin class-switch recombination defects (CSR-D) are rare primary immunodeficiencies characterized by impaired production of switched immunoglobulin isotypes and normal or elevated IgM levels. They are caused by impaired T:B cooperation or intrinsic B cell defects. However, many immunoglobulin CSR-Ds are still undefined at the molecular level.
Objective: This study's objective was to delineate new causes of immunoglobulin CSR-Ds and thus gain further insights into the process of immunoglobulin class-switch recombination (CSR).
Methods: Exome sequencing in 2 immunoglobulin CSR-D patients identified variations in the INO80 gene. Functional experiments were performed to assess the function of INO80 on immunoglobulin CSR.
Results: We identified recessive, nonsynonymous coding variations in the INO80 gene in 2 patients affected by defective immunoglobulin CSR. Expression of wild-type INO80 in patients' fibroblastic cells corrected their hypersensitivity to high doses of γ-irradiation. In murine CH12-F3 cells, the INO80 complex accumulates at Sα and Eμ regions of the IgH locus, and downregulation of INO80 as well as its partners Reptin and Pontin impaired CSR. In addition, Reptin and Pontin were shown to interact with activation-induced cytidine deaminase. Finally, an abnormal separation of sister chromatids was observed upon INO80 downregulation in CH12-F3 cells, pinpointing its role in cohesin activity.
Conclusion: INO80 deficiency appears to be associated with defective immunoglobulin CSR. We propose that the INO80 complex modulates cohesin function that may be required during immunoglobulin switch region synapsis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382329 | PMC |
http://dx.doi.org/10.1016/j.jaci.2014.08.030 | DOI Listing |
DNA Repair (Amst)
August 2025
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Laboratory of Genome Diversification & Integrity, Berlin, Germany; Charité-Universitätsmedizin Berlin, Berlin 10117, Germany. Electronic address:
The ability of B lymphocytes to diversify immunoglobulin (Ig) genes is central to the generation of high-affinity, class-switched antibodies and the establishment of effective humoral immunity. This diversification is achieved through three DNA remodeling processes that occur at defined stages of B cell development and maturation: V(D)J recombination, somatic hypermutation (SHM), and class switch recombination (CSR). These reactions all rely on the induction of programmed DNA lesions at Ig genes and their productive resolution by ubiquitous DNA repair pathways.
View Article and Find Full Text PDFImmunol Rev
September 2025
Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Humoral immune responses are critical for protection against immune challenge by pathogens and transformed cells, while dysregulated antibody production is a hallmark of autoimmune diseases. T follicular helper (Tfh) cells are central to the development of humoral immunity, regulating B-cell maturation, including immunoglobulin class switch recombination and somatic hypermutation, and development of memory B and antibody-producing plasma cells. These events occur as B cells migrate to and differentiate within B cell follicles of secondary lymphoid organs, with this classical program of follicular B cell maturation providing systemic immune protection.
View Article and Find Full Text PDFScand J Immunol
August 2025
Department of Biomedicine, Aarhus University, Aarhus, Denmark.
B cells are essential in the immune system, driving antibody production, cytokine secretion and antigen presentation. Studies in mouse models have illuminated key mechanisms underlying B-cell activation, differentiation, class-switch recombination and somatic hypermutation. However, the extent to which these findings translate to human biology remains unclear.
View Article and Find Full Text PDFImmunol Cell Biol
September 2025
Vaxine Pty Ltd, Warradale, Adelaide, SA, Australia.
Advax is a delta inulin polysaccharide adjuvant shown in animal models to enhance and accelerate influenza vaccine protection. A clinical trial was conducted in 109 healthy adult participants aged 18-70 years randomized to receive a single intramuscular seasonal trivalent influenza vaccine (TIV) alone or formulated with 5 or 10 mg Advax adjuvant to explore the effect of the adjuvant on the humoral immune response. The addition of Advax 10 mg to TIV accelerated the rise in serum influenza-specific antibodies, with this group exhibiting significantly higher increases in hemagglutinin inhibition (HAI) against 3 of the 3 vaccine serotypes at 7 days post-vaccination (7 dpv), 2 at 14 dpv and 1 at 21 dpv.
View Article and Find Full Text PDF